Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.
Daniel P PetrylakYohann LoriotDavid R ShafferFadi BraitehJohn D PowderlyLauren C HarshmanPaul ConklingJean-Pierre DelordMichael GordonJoseph W KimIndrani SarkarKobe YuenEdward E KadelSanjeev MariathasanCarol O'HearSujata NarayananMarcella FassòSusheela CarrollThomas PowlesPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Atezolizumab was generally well tolerated in patients with mCRPC, with a safety profile consistent with other tumor types. In heavily pretreated patients, atezolizumab monotherapy demonstrated evidence of disease control; however, its limited efficacy suggests a combination approach may be needed.